What is it about?

Mycophenolate mofetil is shown to be more effective in the long-term care of pediatric proliferative lupus nephritis. Renal function is better preserved over time for children and youth with this disease than other immunosuppressive therapies.

Featured Image

Why is it important?

Clinical care may be guided by this finding for children and youth with proliferative lupus nephritis.

Perspectives

This is a novel finding using real data collected with patients who were regularly seen at a pediatric care center over a period of more than 30 years. These patients were of a multicultural background and diagnosed with definite proliferative lupus nephritis. The results show that renal function is maintained better by mycophenolate mofetil than other immunosuppressive agents in the long-term care. Considering also the better safety profile associated with mycophenolate mofetil, this therapy is therefore potentially very useful in the treatment of this disease.

Mr Simon Y. Tian
University of Toronto

Read the Original

This page is a summary of: Comparative Effectiveness of Mycophenolate Mofetil for the Treatment of Juvenile-Onset Proliferative Lupus Nephritis, Arthritis Care & Research, November 2017, Wiley,
DOI: 10.1002/acr.23215.
You can read the full text:

Read

Contributors

The following have contributed to this page